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ORIGINAL ARTICLE
Clinical Course of Two Children with Unstable Hemoglobins: The Effect of
Hydroxyurea Therapy
Harri€et M. Looversa, Nienke Tammingab, Andre B. Muldera and Rienk Y. J. Tammingab
aDepartment of Laboratory Medicine, Department of Hematology, University Medical Center Groningen (UMCG), the Netherlands; bPaediatric
Hematology and Oncology, Beatrix Children’s Hospital, University Medical Center Groningen, the Netherlands
ABSTRACT
Case reports on the effect of hydroxyurea (HU) therapy for unstable hemoglobins (Hbs) are sparse; only
three adult cases have been reported. We report for the first time on the effect of HU therapy in chil-
dren carrying unstable Hbs. The first case concerns a female child with a familial history of chronic
hemolytic anemia. She was diagnosed with Hb Volga (HBB: c.83C>A) at the age of 7 months. At age 6,
treatment options were reconsidered due to increasing fatigue and decreasing Hb concentration. The
second case also concerns a female child with chronic hemolytic anemia and icterus since the age of 5.
She was diagnosed with Hb K€oln (HBB: c.295G>A) at the age of 9. At age 10, treatment options were
reconsidered due to decreased general condition and poor school performance. Both children were
started on HU therapy. The child with Hb Volga showed reduced clinical symptoms and increased aver-
age Hb concentrations. She has been on HU therapy for over 7 years at preparation of this manuscript.
The child with Hb K€oln showed decreasing Hb concentrations upon start of therapy; clinical symptoms
did not improve. Therapy was discontinued after 31=2 months. The Hb Volga case report suggests that
HU therapy could improve clinical symptoms in some patients with unstable Hbs. Based on these and
previously published cases, it was speculated that response can be predicted by the percentage of Hb
F and reticulocyte counts.
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Unstable hemoglobins (Hbs) present a subgroup of rare var-
iants with clinical consequences. A mutation on either the
a or b chain affects the stability of the protein, causing Hb
to precipitate [reviewed by Williamson (1)]. Variants fre-
quently show a dominant pattern of inheritance. Depending
on the nature of the variant, very mild to life-threatening
hemolytic anemia is observed. At the moment, over 30 var-
iants of the a chain and 100 variants of the b chain have
been listed as unstable Hbs (2). Due to the broad range and
low prevalence of variants, no guidelines or recommenda-
tions on treatment are available. In mild cases, supportive
and preventive measures might suffice. These measures
include folic acid supplementation, infection prevention and
restrictive use of oxidative drugs. In more severe cases,
splenectomy is often contemplated. However, splenectomy is
associated with an increased risk of infections with encapsu-
lated bacteria and thromboembolic events, whereas chronic
hemolysis is not always resolved. Hydroxyurea (HU) therapy
might offer a suitable alternative, though reports on HU
therapy for unstable Hbs are sparse (3,4).
The benefits of HU therapy in adults and children with
sickle-cell anemia has been demonstrated in many reports.
Improved laboratory values are observed, along with reduced
pain crises, transfusion requirements, hospitalizations and
mortality [reviewed by McGann and Ware (5)]. Few clinical
side effects have been reported; reversible cytopenia and
mild gastrointestinal upset being frequently encountered. No
evidence was present to suggest effects on growth rate, fertil-
ity, teratogenicity or risk of malignancies, even with long-
term exposure (5–7). Hydroxyurea therapy is now advocated
to be part of standard care for sickle-cell anemia; the
National Heart, Lung and Blood Institute (NHLBI) guideline
recommends the drug use to be offered to parents as early
as the age of 9 months for children with homozyogous Hb S
(HBB: c.20A>T) or Hb S-b0-thalassemia (Hb S-b0-thal)
(5,8). Based on the mild and reversible side effects of HU
therapy and the possible benefits, HU therapy is an attractive
option for patients with unstable Hbs. This report is the first
to describe the effect of HU therapy on the clinical course of
children with unstable Hbs. The clinical course of a female
child with Hb Volga [b27(B9)Ala!Asp; HBB: c.83C>A]
and another female child with Hb K€oln [b98(FG5)Val!Met;
HBB: c.295G>A] are presented.
Case reports
Patient 1 is a female child, diagnosed with Hb Volga at the
age of 7 months. A familial history of chronic hemolytic
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anemia was present; the father and several paternal relatives
are heterozygous for the Hb Volga mutation. At the time of
diagnosis, growth and development was according to age
and unremarkable. Laboratory parameters were age appro-
priate, with the exception of the presence of Heinz bodies
and basophilic stippling in the peripheral blood smear. Until
the age of 6, a satisfactory clinical condition was obtained
only with folic acid supplementation. The main observations
were recurrent infections, increasing icterus and increasing
fatigue. The spleen was palpable from age 2 onwards. Two
red blood (RBC) cell concentrates were transfused during a
period of pneumonia at age 4.
At the age of 6, treatment options were reconsidered due
to increasing fatigue and decreasing Hb concentration. Size
of spleen had increased up to 8 cm below the costal margin.
Splenectomy was considered but rejected due to familial his-
tory. The father underwent splenectomy, resulting in
improvement of clinical symptoms of his Hb Volga.
However, pulmonary embolism with deep vein thrombosis
of the left lower extremity was diagnosed a year after splen-
ectomy. Deep vein thrombosis of the right lower extremity
occurred a year after. A paternal uncle carrying Hb Volga
also suffered a thrombolic event after splenectomy.
Subsequently, HU therapy was started at 10mg/kg/day and
increased up to 25mg/kg/day after 1 month. Hemoglobin
concentrations increased from 7.6 g/dL at start of therapy to
10.6 g/dL after 10 months of therapy (Figure 1A). Clinically,
symptoms of fatigue improved significantly within 2 months;
sport activities were started. At age 7, a cholecystectomy was
performed to resolve cholelithiasis. At age 9, during a period
of pneumonia, a neutrophil count less than 1.0 109/L
resulted in a HU dose reduction; Hb concentration and clin-
ical condition warranted transfusion of one RBC concen-
trate. At age 11, a Parvo B19 infection resulted in an aplastic
crisis. Hydroxyurea therapy was temporarily discontinued,
restarted at 14mg/kg/day after 3 months and increased to
19mg/kg/day after 1 month of restarting the therapy. Hb F
percentages increased to 24.0% after 5 months of restart. At
age 12 to 13, the HU dose could not be increased according
to weight due to neutropenia (acceptable neutrophil count
set at 1.0 109/L with the latest dose of 14mg/kg/day result-
ing in Hb F and Hb levels similar to levels before therapy
(Hb F 19.0% and Hb 8.5 g/dL; Figure 1A). The presence of
hypersplenism could be responsible to some degree for the
limitations in HU dosage. At age 13, HU therapy had been
continued for more than 7 years, reversible cytopenia and
mild gastrointestinal upset upon an increase in dose having
been the only reported side effects. In these 7 years, mean
Hb levels were 9.8 g/dL (period of treatment stopped due to
aplastic anemia not included), with mean levels of 8.8 g/dL
before start of treatment (Table 1, Figure 1). Ferritin levels
were well above lower limit of reference before and during
treatment (Table 1; reference values 9.0–126.0 lg/L). Hb F
percentages ranged from 19.0% to 31.0%, with highest Hb F
percentages at times of highest HU dose (Figure 1A).
Hemolytic parameters [bilirubin and lactate dehydrogenase
(LDH)] did not improve upon therapy (Table 1, Figure 1A).
The size of spleen remained within 8–10 cm below the costal
margin during age 6 to 13.
Patient 2 is a female child, diagnosed with Hb K€oln at
the age of 9 years. Extensive laboratory investigations were
performed to explain a history of chronic hemolytic
anemia and icterus. An abnormal Hb fraction was detected
by isoelectric focusing (IEF); percentages of Hb A, Hb A2,
Hb F and Hb K€oln were 88.8, 3.2, 1.8 and 6.2%, respect-
ively. Sequence analysis of patient and parents indicated a
de novo Hb K€oln mutation. Clinical symptoms at age 9
were restricted to fatigue for which infrequent RBC trans-
fusions were given during periods of general malaise. Folic
acid values were monitored, maintaining levels close to
and above upper limit of reference of 30.0 nmol/L from
age 9 to age 17.
At age 10, treatment options were reconsidered due to
decreased general condition and poor school performance.
Splenectomy was considered, but rejected due to the mild
clinical course expected for Hb K€oln, lack of reports showing
a beneficial effect in patients with Hb K€oln and substantial
side effects of splenectomy. Instead, HU therapy was started
at 12.5mg/kg/day and increased to 25mg/kg/day in subse-
quent months. Over a 3-month period, an increase in fatigue
and a further decline in school performance were observed.
Hemoglobin concentrations decreased from 12.4 to 11.3 g/
dL, Hb F percentages remained below 1.0% and thrombocyte
counts decreased to below the lower limit of reference
(Figure 1B, Table 2). Hemolytic parameters did not improve
upon therapy (Figure 1B, Table 2). Consequently, HU ther-
apy was discontinued. In subsequent years, she continued to
receive folic acid supplementation and incidental RBC trans-
fusions. At age 12, iron chelation was prescribed for half a
year to counteract iron overload (highest measured ferritin
level was 788.0 lg/L). At age 13, cholecystectomy was per-
formed to resolve cholelithiasis. At age 18, clinical symptoms
are mainly restricted to fatigue; transfusions are sporadically
indicated and the spleen is not palpable.
Discussion
Hydroxyurea offers a promising therapy for patients with
unstable Hbs. However, at present, only two publications are
available of patients with unstable Hbs being treated with
HU. These publications describe three young adults with a
history of chronic hemolytic anemia, for which splenectomy
had been performed in early childhood (3,4). With the pre-
sent report included, the effect of HU therapy is now
described for five patients and five different unstable Hbs at
different stages of life. A 31-year-old female with Hb
Templeuve (described only once) [b139(H17)-
b140(H18)Asn-Ala!Thr] (3) showed reduced extramedul-
lary hematopoiesis and thrombocytosis upon HU therapy.
Hemoglobin levels increased from 6.7 to 7.5 g/dL within a
year of therapy (3). A 24-year-old male with Hb Perth (HBB:
c.98T>C) showed reduced acute hemolytic episodes and
thrombocytosis. Occurrence of a thrombo-embolic event was
associated with a temporary stoppage of HU therapy.
Hemoglobin levels during HU therapy were comparable to
levels before therapy (3). The patient with Hb Volga repre-
sents the third case with improved clinical symptoms attrib-
uted to HU therapy.
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In homozygous Hb S patients, the primary benefits of
HU therapy are attributed to the induction of Hb F expres-
sion, though additional mechanisms (e.g. increased nitric
oxide levels) could be important (5). Induction of Hb F is
accomplished in the majority of homozygous Hb S patients.
Furthermore, higher Hb F levels during therapy are associ-
ated with higher baseline percentage of Hb F and reticulo-
cyte counts (9–12). For unstable Hbs, the three patients with
Figure 1. Laboratory parameters before and during HU treatment of patient with Hb Volga (left panels) and Hb K€oln (right panels). Start of HU therapy is indicated
by an arrow in the top panels. Period of cholelithiasis (1), pneumonia (2), and Parvo B19 induced aplastic crisis, requiring red blood cell transfusions (3), are indicated
with numerals for the patient with Hb Volga. Percentages of Hb K€oln are shown by a dashed line with open circles. Hb Volga was not detectable by IEF, but a het-
erozygous presence of the mutation was confirmed by sequencing.
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beneficial effects of HU therapy showed base line Hb F
percentages>2.0% and induction of Hb F up to 24.0%. In
the case of Hb Volga, Hb F and Hb levels showed a clear
correlation with HU dose, with limited effect at an HU dose
of 14mg/kg/day. The patient with Hb K€oln is the only
patient for whom a decline in clinical performance as well as
Hb levels was observed. Compared to the other patients, she
had the lowest Hb F values and reticulocyte counts before
and during therapy. For the fifth patient, a 26-year-old male
with Hb Mainz (HBB: c.296T>A) a direct beneficial or
adverse effect of HU therapy cannot be deduced from the
report as other therapies were started simultaneously to
resolve pulmonary hypertension and hemosiderosis.
However, Hb F values during therapy were relatively low
and blood counts did not change (4).
These case reports indicate that HU therapy could
improve clinical symptoms in at least some patients with an
unstable Hb. It is tempting to speculate that response might
be predicted by baseline percentage of Hb F and reticulocyte
counts. However, the amount of published cases is still too
limited to offer a valid prediction of patients who will bene-
fit from HU therapy.
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Hb (g/dL) 8.8 (7.6–9.3) 9.8 (7.9–10.3)
MCV (fL) 79.0 (78.0–82.0) 104.0 (98.0–108.0)
Reticulocytes (%) 148.0 (104.0–200.0)c 107.0 (72.0–155.0)
Leukocytes (109/L) 8.2 (6.5–13.5) 3.4 (1.9–5.2)
Neutrophilic granulocytes (109/L) 3.5 (3.3–3.7) 1.6 (0.9–2.4)
Thrombocytes (109/L) 295.0 (159.0–593.0) 106.0 64.0–150.0)
Bilirubin (lmol/L) 180.0 (142.0–224.0) 218.0 (141.0–310.0)b
Lactate dehydrogenase (U/L) 929.0 (659.0–1197.0) 940.0 (655.0–1201)
Ferritin (lg/dL) 40.0 86.0 (32.0–161.0)
Hb F (%) 19.0c 24.0 (19.0–31.0)
aPeriod of aplastic anemia, requiring RBC transfusions, not included.
bPeriod of cholelithiasis not included.
cValue at age 7 months not included. See Figure 1 for the indication of Hb,
reticulocytes, bilirubin and Hb F values during excluded periods.






Hb (g/dL) 12.0 (11.6–12.4) 12.0 (11.3–12.6)
MCV (fL) 88.0 (86.0–89.0) 103.0 (99.0–109.0)
Reticulocytes (%) 44.0 (37.0–50.0) 39.0 (36.0–44.0)
Leukocytes (109/L) 8.3 (6.5–10.4) 5.1 (4.9–5.5)
Neutrophilic granulocytes (109/L) 7.2 (5.8–8.3) 2.7 (2.5–2.9)
Thrombocytes (109/L) 185.0 (14.9–203.0) 140 (109.0–158.0)
Bilirubin (lmol/L) 38.0 (35.0–42.0) 38.0 (36.0–40.0)
Lactate dehydrogenase (U/L) 427.0 (422.0–432.0) 449.0 (392.0–519.0)
Ferritin (lg/dL) 161.0 ND
Hb F (%) <1.4 (<1.0–1.8) <1.0
Hb K€oln (%) 7.2 (6.2–8.2) 5.3 (6.0–6.4)
ND: not done.
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